You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program
Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017
The conference focused on new insights into PIDs’ diagnosis and therapies
It is the active component of the medicinal product, the one responsible for its healing effect.
The molecules of a drug passing from the site of delivery into the bloodstream.